Literature DB >> 16418873

The efficacy of human schistosomicide treatment may depend on the rate of transmission.

Nelmar García1, Gina Isturiz, Silvia Aular, Renzo Nino Incani.   

Abstract

The efficacy of different treatment protocols in humans infected with Schistosoma mansoni at sites with different transmission conditions was evaluated by the disappearance of anti-worm intestine IgM antibodies in an indirect fluorescence antibody test (IgM-IFT) and anti-egg antibodies in the circumoval precipitin test (COPT). Patient sera coming from sites of active low transmission (ALT), active high transmission (AHT) and low interrupted transmission (LIT) from Venezuela were studied. Chemotherapy protocols were (1) ALT, 60 mg/kg praziquantel (Pzq60); (2) AHT, one dose of 40 mg/kg Pzq followed by one dose of 20 mg/kg oxamniquine for one group and one dose of 40 mg/kg Pzq alone for the other group; (3) LIT, one dose of 40 mg/kg Pzq repeated every 3 months up to three doses. Cure rates occurred mostly between 3 and 12 months with the exception of Pzq60-ALT where it was evident before 3 months. Higher cure rates were evident in both places of low transmission (ALT and LIT) and the lowest in the AHT regardless of the treatment protocol. Cure was more evident with COPT compared to IgM-IFT. The rate of serological cure appears then to depend on the previous state of transmission. The differential cure rate evaluated by both techniques is probably due to the persistence of antibodies against antigens in different stages of the parasite.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418873     DOI: 10.1007/s00436-005-0047-1

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  17 in total

1.  Anti-egg precipitins in the serum of humans infected with Schistosoma mansoni.

Authors:  J OLIVER-GONZALEZ
Journal:  J Infect Dis       Date:  1954 Jul-Aug       Impact factor: 5.226

2.  A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of schistosoma mansoni.

Authors:  H Y Kanamura; L C Dias; R M da Silva; C M Glasser; R M Patucci; S A Vellosa; J L Antunes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1998 Mar-Apr       Impact factor: 1.846

3.  Activity of oxamniquine at skin, pulmonary and sexual maturation phases, on a Schistosoma mansoni strain (R1) previously reported as resistant at the adult phase.

Authors:  P M Coelho; F Ribeiro; R T Mello; F C Lima e Silva; J A Nogueira-Machado
Journal:  Mem Inst Oswaldo Cruz       Date:  1998       Impact factor: 2.743

4.  Antigenicity of adult Schistosoma mansoni alkaline phosphatase.

Authors:  F H Pujol; I M Cesari
Journal:  Parasite Immunol       Date:  1990-03       Impact factor: 2.280

5.  Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine.

Authors:  L C da Silva; J M Zeitune; L M Rosa-Eid; D M Lima; R H Antonelli; C H Christo; A Saez-Alquezar; A de C Carboni
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1986 May-Jun       Impact factor: 1.846

6.  Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil.

Authors:  K Zwingenberger; J A Queiroz; U Poggensee; J E Alencar; J Valdegunas; F Esmeralda; H Feldmeier
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1987 Sep-Oct       Impact factor: 1.846

7.  Schistosoma mansoni: immunodiagnosis is improved by sodium metaperiodate which reduces cross-reactivity due to glycosylated epitopes of soluble egg antigen.

Authors:  B Alarcón de Noya; C Colmenares; H Lanz; M A Caracciolo; S Losada; O Noya
Journal:  Exp Parasitol       Date:  2000-06       Impact factor: 2.011

8.  [Immunofluorescent reaction of antibodies directed against antigens from the intestinal epithelium of Schistosoma mansoni. III. Study of the reactivity of monoclonal antibodies].

Authors:  M Appriou; J Tribouley-Duret; J Tribouley
Journal:  Ann Parasitol Hum Comp       Date:  1986

9.  Collaborative study on antigens for immunodiagnosis of schistosomiasis.

Authors:  K E Mott; H Dixon
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

10.  The Venezuelan experience in the control of schistosomiasis mansoni.

Authors:  R N Incani
Journal:  Mem Inst Oswaldo Cruz       Date:  1987       Impact factor: 2.743

View more
  4 in total

1.  Preliminary characterization of an adult worm "vomit" preparation of Schistosoma mansoni and its potential use as antigen for diagnosis.

Authors:  Sandra Planchart; Renzo Nino Incani; Italo Mario Cesari
Journal:  Parasitol Res       Date:  2007-02-20       Impact factor: 2.289

2.  Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions.

Authors:  Rashida Barakat; Nadia E Abou El-Ela; Soraya Sharaf; Ola El Sagheer; Sahar Selim; Hatem Tallima; Maaike J Bruins; Kevin B Hadley; Rashika El Ridi
Journal:  Am J Trop Med Hyg       Date:  2015-01-26       Impact factor: 2.345

3.  Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.

Authors:  Carla L Black; Michelle L Steinauer; Pauline N M Mwinzi; W Evan Secor; Diana M S Karanja; Daniel G Colley
Journal:  Trop Med Int Health       Date:  2009-02-14       Impact factor: 2.622

Review 4.  The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD).

Authors:  Amélie M Julé; Michel Vaillant; Trudie A Lang; Philippe J Guérin; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2016-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.